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CTN Transplant Trials vs. Investigator Initiated Transplant Trials
U of M Investigator
Initiated Trials
DM hours
prior to
enrollment (1) Accrual
Date
1st patient
enrolled
Screening
Hours
Total Screen
hrs/ patient
DM Hr
After 1st
Enrollmment (2)
Total DM
Hrs/patient
Investigated Initiated Transplant
Conditioning (elderly AML)
28 12 05/18/2007 22 1.83 451 37.58
Investigator Initiated Transplant
Conditioning (CloBu4)
23 15 10/09/2007 30 2.00 305 20.33
Ph II Trial of Adjuvant Cellular
Immunotherapy for High-Risk
Hematologic Malignancy After
Reduced Intensity Allo SCT
Unk (3) 26 07/08/2003 97 3.73 1898 73.00
The addition of Etanercept to
Standard GVHD prophy in
Patients undergoing a full
intensity Unrelated donor
HSCT for the prevention
for Transplant Related
Complications
Unk (3) 71 12/06/2004 110 1.55 1770 24.93
Average
Screening
Hours/patient
2.28 Average DM
hours/patient
after 1st
enrollment
38.96
CTN Trials DM Hours
Prior to 1st
Enrollment (1)
Accrual Date 1st
Patient
Enrolled
Screening Hours Total Screen
Hrs/pt
DM Hr
after 1st
Enrollment (2)
Total DM
Hrs/patient
CTN 0501 71 4 02/03/2007 21 5.25 540 135
CTN 0401 28 11 12/06/2006 92 8.36 665 60.45
CTN 0402 150 10 01/04/2007 59 5.90 465 46.50
CTN 0201 31 12 11/22/2006 124 10.33 475 39.58
Average
Screening
Hours/patient
7.46 Average DM
hours/patient
after 1st
enrollment
70.38
(1) From ‘‘first effort logged’’ to
day prior to first enrollment
(2) Hours from 1st patient
enrolled through 5/30/2008
(3) First patient enrolled prior
to initiation of time tracker
96 Poster Session-Ipatient, likely due to more comprehensive testing to evaluate eligi-
bility, and 3) Differences in the amount of data collected may
account for some portion of the different expenditures in time
per patient. While potential savings are unlikely to be as high as
the total cost differential, at our center alone the total additional
expense for patients enrolled to the four CTN trials is almost
$33,000 for the effort reporting period examined. If CTN were
to write future protocols in a manner that allowed sites to follow
their institutional CPG whenever possible, there could be a signifi-
cant savings of time and money.263
SPECIALIZATION: FOCUSED EFFORT PRODUCES INCREASED ACCESS TO
BLOOD/MARROW TRANSPLANT PROGRAM
McClain, K.A. Baylor University Medical Center, Dallas, TX
Purpose: Due to the rising cost of healthcare and current eco-
nomic environment, many employers have made significant changes
to the healthcare coverage offered to their employees over the last
three to five years. Anticipating an increase in the number of patients
referred to our transplant program with benefit design limitations or
exclusions, as well as increased out-of-network referrals, a dedicated
Transplant Benefit Specialist (TBS) was hired to attempt to resolve
these issues on a case-by-case basis. Prior to implementing this staff-
ing change, only 11% of out-of-network blood/marrow transplant
patients were able to stay at Baylor University Medical Center via
a negotiated individual patient agreement between the payor, hospi-
tal and/or transplant physicians.
Method:TheTBS acts as the liaison between and among the hos-
pital, transplant physicians, payor, patient and employer ensuring
that all parties have all pertinent information in order to make aneducated decision on completing a one-time individual patient
agreement. The TBS advocates on behalf of the patient by providing
the following categories of information to the payor: clinical situa-
tion of the patient, BUMC’s outcomes for the particular transplant
type, rates/language available. In situations where a benefit design
maximum applies or a service is excluded from a policy, the TBS
assists the patient in submitting an exception request to the payor
or employer. The exception request typically includes a letter from
the consulting physician outlining the patient’s clinical situation
and suggested treatment protocol, a letter from the patient, as well
as a formal exception request letter from the TBS providing perti-
nent outcomes.
Results:The percent of converted out-of-network blood/marrow
cases increased from 11% in FY 05 to 62% in FY 07. The ability to
trend benefit design issues by payor has also resulted in changes to
the standard benefit offerings of major payors that previously were
outliers in our market.
Conclusion: A focused effort on this subset of patients dramati-
cally increased their access to our blood/marrow transplant program.
The data collected by the TBS has been a valuable tool used to edu-
cate payors and employers about their benefit design selection and its
impact on actual patient lives.264
DOCUMENTING DISEASE RESPONSE IN TRANSPLANT PATIENTS FOR THE
PURPOSE OF ACCURATE REPORTING TO THE CIBMTR
Thomas, T.K. St. Louis Children’s Hospital, Washington University,
St. Louis, MO
Background: Extracting accurate and relevant details regarding
disease response at fixed time-points as required by the Center for
